menu
    • menu
    [{"orgOrder":0,"company":"Affinivax","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Series B Financing","leadProduct":"MAPS Pneumococcal vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Affinivax","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"","sponsorNew":"Affinivax \/ Viking Global Investors","highestDevelopmentStatusID":"8","companyTruncated":"Affinivax \/ Viking Global Investors"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ASP3772","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Astellas Pharma"},{"orgOrder":0,"company":"Affinivax","sponsor":"Rock Springs Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"ASP3772","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Rock Springs Capital","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Rock Springs Capital"},{"orgOrder":0,"company":"Affinivax","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"Staphylococcus aureus vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Affinivax \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax \/ CARB-X"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ASP3772","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Astellas Pharma Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Astellas Pharma Inc."},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"2","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"Affinivax","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"24-valent Streptococcus Pneumoniae Vaccine","moa":"B-Cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ Affinivax","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Affinivax"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"24-Valent Pneumococcal Vaccine","moa":"B-Cell antibody","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"Affinivax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"AFX3772","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Affinivax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ Not Applicable"},{"orgOrder":0,"company":"Affinivax","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"AFX3772","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Affinivax","amount2":3.2999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":3.2999999999999998,"dosageForm":"Injectable\/Injection","sponsorNew":"Affinivax \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Affinivax \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by Affinivax

    Menu

    Affinivax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFX3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : $3,300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            GSK Completes Acquisition of Affinivax, Inc.

                            Details : The acquisition of Affinivax with GSK’s strategy of building a portfolio of specialty medicines and vaccines. It includes a next-generation 24-valent pneumococcal vaccine ASP3772 (AFX3772), which is based on the innovative Multiple Antigen Presenting S...

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : $2,100.0 million

                            August 16, 2022

                            Lead Product(s) : AFX3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : GSK

                            Deal Size : $3,300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AFX3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine

                            Details : Affinivax’s lead MAPS pneumococcal vaccine candidate is AFX3772, which has successfully completed a Phase 2 study in older adults, with a current clinical study in toddlers and planned study in infants.

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : AFX3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 24-Valent Pneumococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : CEPI

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affinivax to Highlight Preclinical Data from COVID-19 MAPSâ„¢ Vaccine Development Program at IMMUNOLOGY 2022â„...

                            Details : AFX3772, lead vaccine candidate targeting Streptococcus pneumoniae, developed using Affinivax’s proprietary MAPS™ (Multiple Antigen-Presenting System) technology platform, is designed to elicit both B-cell and T-cell immune protection.

                            Brand Name : AFX3772

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 02, 2022

                            Lead Product(s) : 24-Valent Pneumococcal Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : CEPI

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 24-valent Streptococcus Pneumoniae Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent Streptococcus pneumoniae Vaccine Cand...

                            Details : Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus ...

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : $65.0 million

                            February 28, 2022

                            Lead Product(s) : 24-valent Streptococcus Pneumoniae Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Astellas Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : CEPI

                            Deal Size : $4.5 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CEPI Partners with Affinivax to Develop a Novel COVID-19 Vaccine to Target Variants

                            Details : The collaborative program aims to establish preclinical proof of concept for a novel vaccine candidate designed to protect against new COVID-19 variants and that is also suitable for use in low- and middle-income countries.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 13, 2021

                            Lead Product(s) : Covid-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : CEPI

                            Deal Size : $4.5 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772

                            Details : The results from the Phase 2 clinical trial demonstrated that ASP3772 was well tolerated. ASP3772 also exhibited an antibody response to each of the 24 polysaccharides, as well as an additional antibody response to the conserved pneumococcal proteins.

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 12, 2021

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Staphylococcus aureus vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : CARB-X

                            Deal Size : $22.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Affinivax Receives CARB-X for up to $22 Million to Advance its Staphylococcus aureus MAPSâ„¢ Vaccine Candidate...

                            Details : Affinivax’s novel vaccine is being developed for the prevention of S. aureus infections, the most common form of staph infections, in high risk adult populations using the company’s Multiple Antigen Presenting System (MAPS™) vaccine technology plat...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 09, 2021

                            Lead Product(s) : Staphylococcus aureus vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : CARB-X

                            Deal Size : $22.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Rock Springs Capital

                            Deal Size : $226.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Affinivax Announces $226 Million Series C Financing to Advance its Pipeline of Novel MAPSâ„¢ Vaccines Targetin...

                            Details : Affinivax’s novel and proprietary MAPS technology platform is designed to enable the development of a new class of vaccines that induce a broad and robust protective immune response to two key immunogenic components.

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 08, 2021

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Rock Springs Capital

                            Deal Size : $226.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Affinivax Announces the Presentation of Phase 1 Clinical Data for its MAPSâ„¢ Vaccine for Streptococcus pneumo...

                            Details : ASP3772 was observed to be safe and well tolerated in adults 18 to 64 years of age. ASP3772 exhibited robust immunogenicity to the 13 pneumococcal serotypes it shares in common with Prevnar13® as well as to an additional 11 serotypes included in ASP3772...

                            Brand Name : ASP3772

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 21, 2020

                            Lead Product(s) : ASP3772

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Affinivax

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MAPS Pneumococcal vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Viking Global Investors

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Affinivax Announces $120 Million Series B Financing to Advance Pipeline of Novel MAPS Vaccines and Immunothera...

                            Details : Proceeds from the Series B financing will be used to continue advancing the company’s MAPS pneumococcal vaccine program and to advance several additional vaccine candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 23, 2020

                            Lead Product(s) : MAPS Pneumococcal vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Viking Global Investors

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth